Apnimed (NASDAQ:APMD – Get Free Report) was upgraded by research analysts at Zacks Research to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.
A number of other research firms have also recently commented on APMD. Lifesci Capital assumed coverage on Apnimed in a research note on Tuesday. They set an “outperform” rating and a $50.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Apnimed in a report on Tuesday. They set an “overweight” rating and a $60.00 price objective for the company. Evercore assumed coverage on shares of Apnimed in a research report on Tuesday. They issued an “outperform” rating on the stock. Wall Street Zen raised shares of Apnimed to a “hold” rating in a research report on Saturday, August 8th. Finally, Bank of America assumed coverage on shares of Apnimed in a research report on Tuesday. They set a “buy” rating and a $41.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Apnimed has a consensus rating of “Moderate Buy” and an average target price of $50.33.
Read Our Latest Analysis on Apnimed
Apnimed Price Performance
Insider Activity
In other news, major shareholder Morningside Venture Investment purchased 312,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the transaction, the insider directly owned 7,152,713 shares of the company’s stock, valued at approximately $114,443,408. This represents a 4.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
About Apnimed
Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.
Featured Articles
- Five stocks we like better than Apnimed
- 3 Stocks Facing New Pressure From Section 338 Tariffs on Canadian Goods
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
